Replacing warfarin for better or worse: identifying patient factors and future directions

Diug, Basia O; Lowthian, Judy A; Dooley, Michael

doi:10.5694/mja12.11863

Topics

Cardiovascular diseases

Care models must consider patient factors to ensure safe and effective use of patient-administered anticoagulants

1 School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC.
2 Alfred Hospital, Melbourne, VIC.

Correspondence: basia.diug@monash.edu

Acknowledgements:

This work was supported by a grant from the National Health and Medical Research Council (436763) and approved by the human research ethics committees of Monash University and Cabrini Health. We thank the patients and general practitioners for participating in the research.

Competing interests:

No relevant disclosures.

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
2. Australian Government Department of Health and Ageing. Review of anticoagulation therapies in atrial fibrillation. Canberra: Commonwealth of Australia, 2012: 171. http://www.pbs.gov.au/info/publication/factsheets/shared/anticoagulation-review (accessed Jun 2013).
3. Nutescu EA, Shapiro NL, Chevalier A, Amin AN. A pharmacologic overview of current and emerging anticoagulants. Cleve Clin J Med 2005; 72 Suppl 1: S2-S6.
4. Tran HA, Chunilal SD, Harper PL, et al; Australasian Society of Thrombosis and Haemostasis. An update of consensus guidelines for warfarin reversal. Med J Aust 2013; 198: 198-199. <MJA full text>
5. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999; 107: 414-424.
6. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993; 153: 1557-1562.
7. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
8. Diug B, Evans S, Lowthian J, et al. The unrecognized psychosocial factors contributing to bleeding risk in warfarin therapy. Stroke 2011; 42: 2866-2871.
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
10. ROCKET AF Study Investigators. Rivaroxaban -- once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159: 340-347.
11. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
12. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-982.
13. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
14. Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012; 5: 480-486.
15. Wallentin L, Yusuf S, Ezekowitz MD, et al; RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
16. Lim SL, Maxwell E. An audit of dabigatran etexilate prescribing in Victoria [letter]. Med J Aust 2013; 198: 314-315. <MJA full text>
17. Lowthian JA, Diug BO, Evans SM, et al. Who is responsible for the care of patients treated with warfarin therapy? Med J Aust 2009; 190: 674-677. <MJA full text>
18. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41: 2731-2738.
19. Lackie CL, Garbarino KA, Pruetz JA. Warfarin therapy for atrial fibrillation in the elderly. Ann Pharmacother 2002; 36: 200-204.

Online responses are no longer available. Please refer to our instructions for authors page for more information.